NYSEAMERICAN:LCTX Lineage Cell Therapeutics - LCTX Earnings Date, Estimates & Call Transcripts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.43 +0.01 (+0.70%) (As of 02/6/2023 05:19 PM ET) Add Compare Share Share Today's Range$1.39▼$1.4650-Day Range N/A52-Week Range$1.02▼$1.79Volume525,660 shsAverage Volume341,815 shsMarket Capitalization$243.07 millionP/E RatioN/ADividend YieldN/APrice Target$5.40 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainShort InterestSocial Media Earnings Summary Upcoming Earnings DateMar. 8EstimatedActual EPS (Nov. 10) -$0.04 Missed By -$0.01 Consensus EPS (Nov. 10) -$0.03 Last Year's Q4 EPS (11/10/2021) -$0.05Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueLCTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LCTX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.Lineage Cell Therapeutics Analyst ForecastsCurrent Year EPS Consensus Estimate: $-0.15 EPSNext Year EPS Consensus Estimate: $-0.17 EPSLCTX Earnings Date and InformationLineage Cell Therapeutics last issued its earnings results on November 10th, 2022. The reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The business earned $3 million during the quarter, compared to the consensus estimate of $4.11 million. Lineage Cell Therapeutics has generated ($0.29) earnings per share over the last year (($0.29) diluted earnings per share). Earnings for Lineage Cell Therapeutics are expected to decrease in the coming year, from ($0.15) to ($0.17) per share. Lineage Cell Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 8th, 2023 based off prior year's report dates.Read More Get Lineage Cell Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for LCTX and its competitors with MarketBeat's FREE daily newsletter. Lineage Cell Therapeutics Earnings History by Quarter Export to ExcelDateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 3/8/2023(Estimated) 11/10/2022Q3 2022($0.03)($0.04)($0.01)($0.04)$4.11 million$3.00 million8/11/2022Q2 2022($0.03)($0.04)($0.01)($0.04)$4.86 million$4.55 million5/12/2022Q1 2022$0.01($0.04)($0.05)($0.04)$12.07 million$5.24 million3/10/2022Q4 2021($0.04)($0.05)($0.01)$0.07$1.20 million$1.20 million 11/10/20219/30/2021($0.05)($0.05)($0.05)$0.56 million$2.27 million 8/12/20216/30/2021($0.03)($0.03)($0.03)$1.05 million$0.51 million 5/13/20213/31/2021($0.04)($0.01)+$0.03($0.11)$1.07 million$0.39 million 3/10/202112/31/2020($0.05)$0.01+$0.06$0.01$1.34 million$0.36 million 11/4/2020Q3 2020($0.05)($0.04)+$0.01($0.03)$0.65 million$0.57 million11/4/2020Q3 2020($0.05)($0.04)+$0.01($0.03)$0.65 million$0.57 million11/4/20209/30/2020($0.05)($0.05)($0.03)$0.65 million$0.57 million 8/6/2020Q2 2020($0.04)($0.04)($0.04)$0.76 million$0.39 million8/6/2020Q2 2020($0.04)($0.04)($0.04)$0.76 million$0.39 million8/6/20206/30/2020($0.04)($0.04)($0.04)$0.76 million$0.39 million 5/7/2020Q1 2020($0.05)($0.06)($0.01)($0.06)$0.93 million$0.51 million5/7/2020Q1 2020($0.05)($0.06)($0.01)($0.06)$0.93 million$0.51 million5/7/20203/31/2020($0.05)($0.06)($0.01)($0.06)$0.93 million$0.51 million 3/12/2020Q4 2019($0.07)($0.03)+$0.04($0.03)$0.60 million$1.24 million3/12/2020Q4 2019($0.07)($0.03)+$0.04($0.03)$0.60 million$1.24 million 3/12/202012/31/2019($0.07)($0.03)+$0.04($0.03)$0.60 million$1.24 million 11/12/2019Q3 2019($0.05)($0.04)+$0.01$0.03$0.94 million$0.57 million11/12/2019Q3 2019($0.05)($0.04)+$0.01$0.03$0.94 million$0.57 million11/12/2019Q3 2019($0.05)($0.04)+$0.01$0.03$0.94 million$0.57 million8/8/2019Q2 2019($0.05)($0.06)($0.01)$0.08$1.04 million$0.78 million8/8/2019Q2 2019($0.05)($0.06)($0.01)$0.08$1.04 million$0.78 million8/8/2019Q2 2019($0.05)($0.06)($0.01)$0.08$1.04 million$0.78 million5/9/2019Q1 2019($0.06)$0.30+$0.36$0.30$0.66 million$0.93 million5/9/2019Q1 2019($0.06)$0.30+$0.36$0.30$0.66 million$0.93 million5/9/2019Q1 2019($0.06)$0.30+$0.36$0.30$0.66 million$0.93 million3/14/2019Q4 2018($0.07)($0.07)$0.21$0.74 million$0.76 million3/14/2019Q4 2018($0.07)($0.07)$0.21$0.74 million$0.76 million3/14/2019Q4 2018($0.07)($0.07)$0.21$0.74 million$0.76 million11/8/2018Q3 2018($0.06)($0.07)($0.01)($0.67)$0.75 million$0.98 million11/8/2018Q3 2018($0.06)($0.07)($0.01)($0.67)$0.75 million$0.98 million11/8/2018Q3 2018($0.06)($0.07)($0.01)($0.67)$0.75 million$0.98 million8/2/2018Q2 2018($0.09)($0.06)+$0.03($0.09)$0.33 million$2.55 million8/2/2018Q2 2018($0.09)($0.06)+$0.03($0.09)$0.33 million$2.55 million8/2/2018Q2 2018($0.09)($0.06)+$0.03($0.09)$0.33 million$2.55 million5/10/2018Q1 2018($0.08)($0.09)($0.01)$0.32$0.83 million$0.70 million5/10/2018Q1 2018($0.08)($0.09)($0.01)$0.32$0.83 million$0.70 million5/10/2018Q1 2018($0.08)($0.09)($0.01)$0.32$0.83 million$0.70 million3/15/2018Q4 2017($0.06)($0.08)($0.02)$0.42$2.38 million$1.00 million3/15/2018Q4 2017($0.06)($0.08)($0.02)$0.42$2.38 million$1.00 million3/15/2018Q4 2017($0.06)($0.08)($0.02)$0.42$2.38 million$1.00 million11/9/2017Q3 2017($0.09)($0.05)+$0.04($0.22)$1.69 million11/9/2017Q3 2017($0.09)($0.05)+$0.04($0.22)$1.69 million11/9/2017Q3 2017($0.09)($0.05)+$0.04($0.22)$1.69 million8/2/2017Q2 2017($0.09)($0.05)+$0.04$0.01$0.38 million8/2/2017Q2 2017($0.09)($0.05)+$0.04$0.01$0.38 million8/2/2017Q2 2017($0.09)($0.05)+$0.04$0.01$0.38 million5/10/2017Q1 2017($0.09)($0.08)+$0.01($0.62)$0.39 million5/10/2017Q1 2017($0.09)($0.08)+$0.01($0.62)$0.39 million5/10/2017Q1 2017($0.09)($0.08)+$0.01($0.62)$0.39 million11/3/2016Q3 2016($0.20)($0.08)+$0.12($0.46)$1.46 million$1.50 million11/3/2016Q3 2016($0.20)($0.08)+$0.12($0.46)$1.46 million$1.50 million11/3/2016Q3 2016($0.20)($0.08)+$0.12($0.46)$1.46 million$1.50 million8/9/2016Q2 2016($0.17)($0.11)+$0.06($0.48)$2.15 million$1.27 million8/9/2016Q2 2016($0.17)($0.11)+$0.06($0.48)$2.15 million$1.27 million8/9/2016Q2 2016($0.17)($0.11)+$0.06($0.48)$2.15 million$1.27 million5/10/2016Q1 2016($0.12)($0.19)($0.07)($0.19)$1.36 million$2.07 million5/10/2016Q1 2016($0.12)($0.19)($0.07)($0.19)$1.36 million$2.07 million5/10/2016Q1 2016($0.12)($0.19)($0.07)($0.19)$1.36 million$2.07 million3/15/2016Q4 2015($0.16)($0.16)($0.16)$1.31 million3/15/2016Q4 2015($0.16)($0.16)($0.16)$1.31 million3/15/2016Q4 2015($0.16)($0.16)($0.16)$1.31 million11/9/2015Q3 2015($0.18)($0.18)($0.18)$2.31 million11/9/2015Q3 2015($0.18)($0.18)($0.18)$2.31 million11/9/2015Q3 2015($0.18)($0.18)($0.18)$2.31 million8/10/2015Q2 2015($0.12)($0.12)($0.12)$2.01 million8/10/2015Q2 2015($0.12)($0.12)($0.12)$2.01 million8/10/2015Q2 2015($0.12)($0.12)($0.12)$2.01 million5/11/2015Q1 2015($0.13)($0.13)($0.13)$1.26 million5/11/2015Q1 2015($0.13)($0.13)($0.13)$1.26 million5/11/2015Q1 2015($0.13)($0.13)($0.13)$1.26 million3/11/2015Q4 2014($0.14)($0.14)($0.14)$1.89 million3/11/2015Q4 2014($0.14)($0.14)($0.14)$1.89 million3/11/2015Q4 2014($0.14)($0.14)($0.14)$1.89 million11/10/2014Q3 2014($0.12)($0.12)($0.12)$1.19 million11/10/2014Q3 2014($0.12)($0.12)($0.12)$1.19 million11/10/2014Q3 2014($0.12)($0.12)($0.12)$1.19 million8/12/2014Q2 2014($0.16)($0.16)($0.16)$1.11 million8/12/2014Q2 2014($0.16)($0.16)($0.16)$1.11 million8/12/2014Q2 2014($0.16)($0.16)($0.16)$1.11 million5/12/2014Q1 2014($0.14)($0.14)($0.14)$1.07 million5/12/2014Q1 2014($0.14)($0.14)($0.14)$1.07 million5/12/2014Q1 2014($0.14)($0.14)($0.14)$1.07 million3/17/2014Q4 2013($0.35)($0.35)($0.35)$1.89 million3/17/2014Q4 2013($0.35)($0.35)($0.35)$1.89 million3/17/2014Q4 2013($0.35)($0.35)($0.35)$1.89 million11/12/2013Q3 2013($0.16)($0.16)($0.16)$0.71 million11/12/2013Q3 2013($0.16)($0.16)($0.16)$0.71 million11/12/2013Q3 2013($0.16)($0.16)($0.16)$0.71 million8/9/2013Q2 2013($0.14)($0.14)($0.14)$1.22 million8/9/2013Q2 2013($0.14)($0.14)($0.14)$1.22 million8/9/2013Q2 2013($0.14)($0.14)($0.14)$1.22 million5/10/2013Q1 2013($0.15)($0.15)($0.15)$0.61 million5/10/2013Q1 2013($0.15)($0.15)($0.15)$0.61 million5/10/2013Q1 2013($0.15)($0.15)($0.15)$0.61 millionLineage Cell Therapeutics Earnings - Frequently Asked Questions When is Lineage Cell Therapeutics's earnings date? Lineage Cell Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 8th, 2023 based off last year's report dates. Learn more on LCTX's earnings history. Did Lineage Cell Therapeutics beat their earnings estimates last quarter? In the previous quarter, Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) missed the analysts' consensus estimate of ($0.03) by $0.01 with a reported earnings per share (EPS) of ($0.04). Learn more on analysts' earnings estimate vs. LCTX's actual earnings. How much revenue does Lineage Cell Therapeutics generate each year? Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a recorded annual revenue of $4.34 million. How much profit does Lineage Cell Therapeutics generate each year? Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a recorded net income of -$43.02 million. LCTX has generated -$0.29 earnings per share over the last four quarters. What is Lineage Cell Therapeutics's EPS forecast for next year? Lineage Cell Therapeutics's earnings are expected to decrease from ($0.15) per share to ($0.17) per share in the next year. More Earnings Resources from MarketBeat Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Apple: What's The Post-Earnings Play?Spotify’s Traffic, Not Earnings is Driving the Stock HigherWhat do Mastercard Earnings Indicate About Consumer Spending? Here’s the Silver Lining with Snap Stock Earnings CollapseZimmer Biomet Beats on Earnings, Growth May be Priced InFord Stock Going Forward After Big Earnings FlopAnalyzing Alaska Air's Recent Earnings Upcoming Earnings: Fiserv (2/7/2023)Vertex Pharmaceuticals (2/7/2023)BP (2/7/2023)Linde (2/7/2023)CME Group (2/8/2023)O'Reilly Automotive (2/8/2023)CVS Health (2/8/2023)Dominion Energy (2/8/2023)Walt Disney (2/8/2023)Emerson Electric (2/8/2023) This page (NYSEAMERICAN:LCTX) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.